Insights

Executive Summary How to win 180-day exclusivity, survive the price erosion curve, and build a future-proof portfolio in a $491B […]

I. The $300 Billion Opportunity Hiding in Plain Sight The most reliable, legally mandated, and fiscally massive cost-containment event in

The 20-year patent term is the most cited number in pharmaceutical business strategy. It is also, in practice, a fiction.

Part I: The Exclusivity Architecture: What Executives Get Wrong About the 20-Year Rule The number ’20 years’ is the most

Why This Cliff Is Different Generic and biosimilar drugs saved the U.S. healthcare system an estimated $3.1 trillion over the

The generic pharmaceutical industry has spent thirty years perfecting a business model that no longer works. The playbook was elegant

A deep-dive strategic guide for pharma IP teams, portfolio managers, R&D leads, and institutional investors on the regulatory, patent, and

Who this is for: IP teams at innovator and generic companies, portfolio managers running LOE models, R&D leads evaluating lifecycle

The Market You’re Actually Competing In The generic drug industry saves the U.S. healthcare system more than $445 billion per